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lipoproteins, lowers LDL-cholesterol on average by 28%. This com-
pound, mipomersen, is injected weekly subcutaneously.
A second agent that inhibits the formation of apoB-containing 
lipoproteins in liver and gut is an inhibitor of microsomal triglyceride 
transfer protein (MTP). This compound lowered LDL-cholesterol by 
50% in patients with homozygous familial hypercholesterolemia. 
A side effect of both classes of drugs is the accumulation of fat in 
the liver.
Proprotein convertase subtilisin/kexin type 9 serine protease 
(PCSK9) is a protease that induces degradation of LDL-receptors. 
Statins increase the concentration of PCSK9, thereby attenuating 
their LDL-cholesterol–lowering effect. Combining statins with inhibi-
tors of PCSK9 has proven to be very effective in LDL-cholesterol 
lowering: injection of monoclonal antibodies to PCSK9 biweekly 
on top of maximal statin therapy lowered LDL-cholesterol by an 
extra 60%. If long-term treatment with these antibodies proves to 
be safe, this will change the treatment of patients with severe familial 
hypercholesterolemia. The near future years will also provide the 
final verdict whether raising HDL-cholesterol by means of inhibition 
of cholesteryl ester transfer protein (CETP) will be of any benefit.
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ANTi-TNF iN oCulAr diSeASeS
I. Süveges*
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Summary: Tumor necrosis factor-alpha (TNF-alpha) plays a role in 
the process of intraocular inflammation that is the cause that the use 
of TNF-alpha inhibitor agents is worldwide spread to treat differ-
ent form of intraocular inflammations. In ophthalmology, anti-TNFs 
are applied in the treatment of uveitis and immune-vasculitis. The 
number of TNF-alpha inhibitors is increasing despite the fact that 
such kind of medication can be used “off-label” in the treatment 
of inflammations. TNF-alpha inhibitors are effective at first in that 
form of uveitis that is connected with systemic immunologic diseases: 
Mo. Behcet, rheumatoid arthritis (especially with juvenile idiopathic 
arthritis), Mo. Chrohn, Wegener granulomatosis, autoimmune dis-
eases (lupus-like syndrome [LLS]). In cases of vasculitis, it can be 
used in giant cell arthritis, Takayasu arthritis, primary angiitis of the 
central nervous system, and Cogan syndrome. Anti–TNF-alpha also 
are effective in cases of autoimmune, noninfectious diseases of the 
eye: Mo. Harada, sympathetic ophthalmia. The most frequent anti–
TNF-alpha that are used are etanercept, adalimumab, and infliximab. 
There are 3 other TNF-alpha inhibitors that are less widespread yet: 
golimumab, certolizumab, and tocilizumab. The advantage of the 
TNF-alpha inhibitors are that they have fewer side effects as corti-
costeroids and immunsuppressives but are more effective. Their only 
disadvantage: they are very expensive.
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New TArgeTS iN The TreATmeNT  
oF rheumAToid ArThriTiS
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Summary: With the increasing needs for better outcome, func-
tion, and quality of life in arthritides and autoimmune diseases, we 
have increasing amounts of information on the major pathogenetic 
pathways underlying rheumatoid arthritis (RA), spondyloarthriti-
des (SpA), lupus, scleroderma, and other rheumatic diseases. After 
decades of reliance on largely empiric approaches in the therapy 
of most of these diseases, the introduction of TNF-alpha–blocking 
agents in the late 1990s revolutionized the therapy of rheumatoid 
arthritis (RA), other arthritides, and connective tissue diseases. 
Numerous pathways have been targeted and almost 10 biologics 
have been registered to treat RA, SpA, and lupus. In addition to 
anti-TNF biologics, further therapies such as anti–IL-6R, CTLA4-
inhibitor, or anti-CD20 agents along with several new experimental 
approaches have since emerged out of improved understanding of 
the immunopathogenesis. In addition to biologics, the first small 
molecular targeted therapies, mostly tyrosine kinase inhibitors, have 
been developed. Most therapies primarily intended for RA, however, 
have failed to show or have shown only marginal benefit in other 
autoimmune rheumatic diseases such as lupus, scleroderma, poly-
myositis, or vasculitides, all of which continue to have a high unmet 
medical need. Challenges to identify novel drug candidates and to 
conduct successful clinical studies for such diseases include the dif-
ferent and highly complex immunopathology as well as clinical 
trial–related issues (eg, the lack of validated, sensitive, and reliable 
end points). Recently, promising new therapeutic approaches have 
emerged. This presentation highlights these advances in autoimmune 
rheumatic diseases.
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Summary: In the last decades, both regulators and manufactur-
ers have used computerized data-mining techniques on reports 
of adverse drug reactions from both health care practitioners and 
consumers to detect drug safety signals, that is, unknown or incom-
pletely documented drug-event associations. The signal detection 
using data from spontaneous reporting system (SRS) databases is 
negatively influenced however by under- and selective reporting as 
well as missing denominators. To overcome some of these shortcom-
ings, in the last 5 years, a number of ongoing international initia-
tives (Sentinel, Protect, OMOP, EU-ADR) has started to explore 
longitudinal observational health care data, including electronic 
health records (EHRs), as an additional source for signal detec-
tion. The ultimate goal of the EU-ADR project was to develop an 
innovative, computerized system for the automatic detection of drug 
safety signals. Using a database network of 7 databases from 3 coun-
tries covering ~30 million European patients, EU-ADR developed 
new methodologies for signal detection and compared the perfor-
mance (both in terms of precision and timing) of signal detection 
using either EHRs or SRS through validation sets. Main findings 
of the project are that EU-ADR is not powered enough to monitor 
infrequently used/captured drugs and associations regarding very 
rare events, while SRS may be more efficient. On the other hand, 
EU-ADR has the most power for signal detection concerning events 
with higher incidences rate and not commonly reported to SRS. In 
this presentation, the overview of methodology and results from 
EU-ADR will be presented and the potentially additional value of 
exploring EHRs in the context of pharmacovigilance will be dis-
cussed.
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STudyiNg TerATogeNiC eFFeCTS oF 
mediCATioN uSe duriNg pregNANCy: 
ChAlleNgeS ANd piTFAllS
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Summary: Depending on the data sources used and the types of stud-
ies included, 29% to 99% of pregnant women in developed countries 
take at least 1 prescribed drug. Although some drugs, such as thalido-
mide and isotretinoin, are classical examples of human teratogens 
(nongenetic risk factors that cause birth defects), the human terato-
genic risks are undetermined for > 90% of prescription drug treat-
ments approved for marketing in the United States since 1980. Due 
to this lack of information, adherence to pharmacologic treatment 
may be discouraged, which may endanger maternal and fetal health, 
or women may choose to terminate their wanted pregnancies based 
on fear of adverse effects. In other pregnancies, fetal development 
may be disturbed by unknown teratogenic exposures that could have 
been avoided. Therefore, high-quality human studies focusing on 
the adverse effects of medication use during pregnancy are urgently 
needed. However, apart from the general methodologic problems in 
epidemiologic research, such as confounding, selection and informa-
tion bias, and limitations in making causal inferences, pharmacoepi-
demiologic studies focusing on birth defects face some important 
problems that are unique to this area of research. During this lecture, 
these problems and some new initiatives in epidemiologic research on 
adverse effects of medication use during pregnancy will be discussed.
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J. Van Gerven*
Centre for Human Drug Research, Leiden, the Netherlands
Summary: In the last decades, several drugs for neuropsychiatric 
indication failed in late stages of development or were withdrawn 
shortly after launch, including disease-modifying compounds for 
dementia (eg, the γ -secretase inhibitor tarenflurbil) and innovative 
drugs for smoking addiction (eg, the CB1-antagonist rimonabant). A 
few years ago, some of the larger pharmaceutical industries decided 
that the financial risk of developing drugs for psychiatric indications 
was too large, and many CNS projects were abandoned. Currently, 
the industry tries to innovate CNS drug development by investing in 
partnerships with expert groups and exploring novel science-driven 
approaches. An essential requirement for a successful drug is that it 
reaches its therapeutic target in the right concentrations during the 
correct time period, and that it avoids levels or targets associated with 
adverse events. In addition, the drug’s mechanism of action needs to 
have a beneficial effect on the pathogenesis or pathophysiology of 
the disease. Most of these aspects can be accurately determined in 
healthy subjects, in the earliest phases of drug development. To some 
extent this also includes indications of therapeutic benefit, because 
many diseases involve well-known physiological processes that are 
also measurable in normal subjects, although therapeutic benefit can 
only be reliably examined in patients. Thus, the predictions of the 
optimal dosing regimen (or the likeliness of failure) of a new drug in 
patients can be significantly enhanced by demonstration of optimal 
pharmacologic activity in every early (and later) study during drug 
development. This lecture will provide several examples, in which 
pharmacologic effect measurements were incorporated into “tradi-
tional” single and multiple ascending dose studies in Phase I. These 
instruments include (but are not limited to) validated effect biomark-
ers such as the NeuroCart CNS test battery (pharmacologic activity 
and beneficial/detrimental effects), PET measurements or continu-
ous CSF-sampling (BBB-penetration), pharmacologic challenge tests 
(pharmacologic activity) or informative positive controls (bench-
marking), and pharmacokinetic/dynamic analysis for data integra-
tion. The examples involve innovative compounds such as partial 
GABA-A-agonists and CB1-antagonists, and the first human studies 
with a fast-dissociating D2-antagonist and an orexin half-antagonist. 
In most of these cases, traditional approaches were misleading, but a 
goal-directed “question-based” application of pharmacologic tools 
in healthy subjects demonstrated brain penetration and meaningful 
functional effects (indicative of therapeutic or detrimental activity), 
which contributed to accurate predictions of therapeutic windows 
in clinical trials.
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Summary: Drug R&D is costly, time-consuming, and has a low suc-
cess rate. The costs exceed 1 billion USD. From the human Phase 
I trial on, the increase is exponential. In the EU, 60% of clinical 
trials applied for every year are sponsored by the pharmaceutical 
industry and 40% by other stakeholders, such as academics. It is 
no wonder, then, that the EU Clinical Trials Directive 2011/20/EC 
incented protest mainly from the academic and SME stakeholders. 
According to the EC, although the Directive brought about impor-
tant improvements in the safety and ethical soundness of clinical 
trials and in the reliability of clinical trials data, on the other hand, 
it led to the fall of the number of applications by 25%. The costs 
have increased. The staff needs for industry sponsors to handle the 
clinical trial authorization process have doubled, with SMEs facing 
an even sharper increase. For noncommercial sponsors, the increase 
in administrative requirements has led to a 98% increase in admin-
istrative costs. Insurance fees have increased by 800% for industry 
sponsors. Although the EC is now about to ease the burdens, it is 
clear that significant resources would be required anyhow. The proper 
and time-conscious conduct of extended, multinational, cross-conti-
nental clinical studies requires sufficient high-quality staff, logistics, 
experience, and knowledge of different regulatory aspects, let alone 
a sound financial background. This can be handled only by the help 
of industry resources at the end. Trends and data underpinning this 
opinion will be demonstrated in the presentation.
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Summary: The efficacy assessment in clinical studies evaluating drug 
effects, or more generally disease management, is generally focused 
on the occurrence of objective clinical or economical outcomes, in 
line with regulatory guidelines. However, there is growing recogni-
tion of the value of capturing wider effects of treatments reported by 
patients in the form of patient-reported outcomes (PROs). A PRO 
is defined as any report of the status of a patient’s health condition 
that comes directly from the patient, without interpretation of the 
patient’s response by a clinician or anyone else. After examining the 
reasons explaining the development of these new clinical research 
